Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Depreciation & Amortization (CF) (2016 - 2025)

Amicus Therapeutics filings provide 16 years of Depreciation & Amortization (CF) readings, the most recent being $1.9 million for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 7.06% to $1.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.5 million, a 12.72% decrease, with the full-year FY2025 number at $7.5 million, down 12.72% from a year prior.
  • Depreciation & Amortization (CF) hit $1.9 million in Q4 2025 for Amicus Therapeutics, up from $1.9 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $2.2 million in Q3 2023 to a low of $1.3 million in Q1 2023.
  • Median Depreciation & Amortization (CF) over the past 5 years was $1.8 million (2025), compared with a mean of $1.8 million.
  • Biggest five-year swings in Depreciation & Amortization (CF): plummeted 40.4% in 2021 and later skyrocketed 73.25% in 2023.
  • Amicus Therapeutics' Depreciation & Amortization (CF) stood at $1.5 million in 2021, then dropped by 13.64% to $1.3 million in 2022, then soared by 66.44% to $2.2 million in 2023, then dropped by 6.46% to $2.0 million in 2024, then fell by 7.06% to $1.9 million in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $1.9 million (Q4 2025), $1.9 million (Q3 2025), and $1.9 million (Q2 2025) per Business Quant data.